SCHEMBL891311

SCHEMBL891311

C/C(C=O)=C/c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 1.00
TSHR P16473 1/20 1.00
AKR1C3 P42330 1/20 0.56
MAPT P10636 3/20 0.50
TDP1 Q9NUW8 2/20 0.50
FBP1 P09467 1/20 0.50
GLA P06280 1/20 0.50
NPC1 O15118 1/20 0.50
POLB P06746 1/20 0.50
RAB9A P51151 1/20 0.50
LMNA P02545 3/20 0.47
RECQL P46063 2/20 0.47
KMT2A Q03164 1/20 0.46
CYP2A6 P11509 1/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.46
HDAC3 O15379 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL186778 1.00 ALDH1A1 (1.00) ALDH1A1TSHRAKR1C3MAPTTDP1
Benzene SCHEMBL28222938 1.00 ALDH1A1 (1.00) ALDH1A1TSHRAKR1C3MAPTTDP1
SCHEMBL230809 1.00 ALDH1A1 (1.00) ALDH1A1TSHRAKR1C3MAPTTDP1
Acrolein SCHEMBL18954136 0.90 ALDH1A1 (0.81) ALDH1A1TSHRAKR1C3MAPTTDP1
Acrolein SCHEMBL18954135 0.90 ALDH1A1 (0.81) ALDH1A1TSHRAKR1C3MAPTTDP1
SCHEMBL13825216 0.89 ALDH1A1 (0.80) ALDH1A1TSHRAKR1C3MAPTTDP1
SCHEMBL11469894 0.87 ALDH1A1 (0.77) ALDH1A1TSHRAKR1C3MAPTTDP1
SCHEMBL11469893 0.87 ALDH1A1 (0.77) ALDH1A1TSHRAKR1C3MAPTTDP1
SCHEMBL11473022 0.82 ALDH1A1 (0.69) ALDH1A1TSHRAKR1C3NPC1RAB9A
SCHEMBL11473020 0.82 ALDH1A1 (0.69) ALDH1A1TSHRAKR1C3NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3784707-B1 STABLE POLYUREA MICROCAPSULE COMPOSITIONS INT FLAVORS & FRAGRANCES INC (US) 2025-12-24 EP claimed
US-20250235136-A1 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2025-07-24 US claimed
CN-114026418-B Improvements in or relating to organic compounds 奇华顿股份有限公司 2024-07-26 CN claimed
US-20240197222-A1 ORAL CARE FLAVOUR FOR IMPROVING HAPPINESS STATE AND METHOD OF ASSESSING GIVAUDAN SA (CH) 2024-06-20 US claimed
US-20240197183-A1 ORAL CARE FLAVOUR FOR IMPROVING INVIGORATION STATE AND METHOD OF ASSESSING GIVAUDAN SA (CH) 2024-06-20 US claimed
US-20240173230-A1 FRAGRANCE COMPOSITION GIVAUDAN SA (CH) 2024-05-30 US claimed
EP-4347760-A1 ORAL CARE FLAVOUR FOR IMPROVING HAPPINESS STATE AND METHOD OF ASSESSING Givaudan SA (CH) 2024-04-10 EP claimed
EP-4347761-A1 ORAL CARE FLAVOUR FOR IMPROVING INVIGORATION STATE AND METHOD OF ASSESSING Givaudan SA (CH) 2024-04-10 EP claimed
EP-4319715-A1 FRAGRANCE COMPOSITION Givaudan SA (CH) 2024-02-14 EP claimed
EP-4257663-A1 FOOD CONTACT SURFACE SANITIZING LIQUID The Procter & Gamble Company (US) 2023-10-11 EP claimed
US-11603506-B2 Product comprising a plastic container and a substance composition SYMRISE AG (DE) 2023-03-14 US claimed
WO-2022234154-A1 ORAL CARE FLAVOUR FOR IMPROVING INVIGORATION STATE AND METHOD OF ASSESSING GIVAUDAN SA (CH) 2022-11-10 WO claimed
WO-2022234153-A1 ORAL CARE FLAVOUR FOR IMPROVING HAPPINESS STATE AND METHOD OF ASSESSING GIVAUDAN SA (CH) 2022-11-10 WO claimed
US-20220334094-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2022-10-20 US claimed
WO-2022214636-A1 FRAGRANCE COMPOSITION GIVAUDAN SA (CH) 2022-10-13 WO claimed
WO-2022128052-A1 MEDICAMENT FOR FIGHTING INFLAMMATORY CONDITIONS OF HUMAN SKIN SYMRISE AG (DE) 2022-06-23 WO claimed
EP-3990596-A2 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan SA (CH) 2022-05-04 EP claimed
CN-114026418-A Improvements in or relating to organic compounds 奇华顿股份有限公司 2022-02-08 CN claimed
EP-0404453-B1 Dimer reduction NOVA PETROCHEMICALS INC (CA) 1994-02-23 EP claimed
EP-0067067-B1 DRY-DEVELOPING NEGATIVE RESIST COMPOSITION FUJITSU LIMITED (JP) 1985-09-25 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240173230-A1 FRAGRANCE COMPOSITION FABP2, FABP5, FAAH2 ALDH1A1 413/4885TSHR 4522/4885AKR1C3 2288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.